
MoonLake Immunotherapeutics (MLTX) Stock Forecast & Price Target
MoonLake Immunotherapeutics (MLTX) Analyst Ratings
Bulls say
MoonLake Immunotherapeutics is advancing a novel tri-specific IL-17A and IL-17F inhibiting Nanobody, SLK, which has demonstrated promising efficacy in clinical trials, particularly in treating hidradenitis suppurativa (HS) and potentially other inflammatory conditions. The positive feedback from key opinion leaders suggests a strong likelihood of superior outcomes in upcoming Phase III trials, supported by the drug's efficacy data compared to established therapies like Cosentyx. Additionally, with HS presenting a significant unmet medical need and rising awareness, there exists potential for substantial market opportunities, bolstered by revenues from other indications such as psoriatic arthritis (PsA).
Bears say
MoonLake Immunotherapeutics faces significant risks that contribute to a negative outlook on its stock, primarily tied to the clinical and regulatory pathways of its lead asset, SLK. Any unforeseen safety issues, suboptimal efficacy results, or pharmacokinetic challenges could hinder ongoing clinical trials, reducing the prospects for success and revenue generation. Furthermore, the company reported a substantial net loss of $44.2 million in the fourth quarter of 2024, and key issues such as inconsistent dose dependency in clinical trials and potential difficulties entering the market against established competitors further exacerbate concerns regarding its financial viability.
This aggregate rating is based on analysts' research of MoonLake Immunotherapeutics and is not a guaranteed prediction by Public.com or investment advice.
MoonLake Immunotherapeutics (MLTX) Analyst Forecast & Price Prediction
Start investing in MoonLake Immunotherapeutics (MLTX)
Order type
Buy in
Order amount
Est. shares
0 shares